ASND Analyst Ratings
Ascendis Pharma A/S (ASND) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $13.86B, listed on NASDAQ, employing roughly 1,189 people, carrying a beta of 0.37 to the broader market. Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Led by Jan Moller Mikkelsen, public since 2015-01-28.
Analyst Ratings
In the October 2026 monthly count, 20 analysts rated ASND: 5 Strong Buy, 15 Buy, 0 Hold, 0 Sell and 0 Strong Sell.
Twelve months earlier, in October 2025: 15 analysts, 3 Strong Buy, 12 Buy, 0 Hold, 0 Sell and 0 Strong Sell.
Price Targets
- Average Target
- $311.17
- Median Target
- $322.50
- High
- $344.00
- Low
- $269.00
- Targets Published, Last 12 Months
- 34
Recent Price Targets
The 5 most recent of 34 price targets published in the last 12 months.
| Date | Firm | Analyst | Target | Price When Posted |
|---|---|---|---|---|
| Oct 15, 2026 | UBS | Not named | $269.00 | $227.00 |
| Sep 16, 2026 | UBS | Not named | $344.00 | $239.77 |
| Sep 15, 2026 | Raymond James | Martin Auster | $287.00 | $264.92 |
| Sep 10, 2026 | H.C. Wainwright | Not named | $344.00 | $260.81 |
| Sep 1, 2026 | Oppenheimer | Leland Gershell | $312.00 | $260.25 |
Recent Upgrades & Downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 25, 2026 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| Sep 15, 2026 | Raymond James | downgrade | Strong Buy | Outperform |
| Sep 2, 2026 | Oppenheimer | maintain | Outperform | Outperform |
| Sep 1, 2026 | Morgan Stanley | maintain | Overweight | Overweight |
| Sep 1, 2026 | Wedbush | maintain | Outperform | Outperform |
Quantitative Rating
ASND carries a model grade of B (overall score 3 of 5), computed from six valuation and financial measures (discounted cash flow, return on equity, return on assets, debt to equity, price to earnings and price to book), each scored 1 to 5. It is not an analyst rating.
How to Read ASND Analyst Coverage
Sell-side equity analysts publish three primary outputs: ratings (Strong Buy / Buy / Hold / Sell / Strong Sell, or firm-specific equivalents), price targets, and EPS / revenue estimate revisions. Rating consensus moves slowly relative to price; it reflects 12-month directional conviction rather than near-term momentum. Price targets are more responsive but typically drift behind realized price during sharp moves. The most actionable signal for options traders is a cluster of ratings actions across multiple firms within a short window, which compresses or expands implied volatility on a horizon of days to weeks and shifts the put-call skew toward the directional consensus. The recent-actions table above shows the five most recent firm-level changes; longer histories live behind aggregator sources.
For event-driven options sizing, pair the consensus rating and target distribution with the implied-volatility surface and dealer-positioning view. Aggressive target hikes from multiple firms tend to tighten put skew (downside protection becomes relatively cheaper); aggressive cuts widen put skew. The size of the IV response in the hours after a rating change is visible on the per-ticker volatility skew page and the gamma-exposure page, both of which show how dealer hedging propagates the analyst-driven flow into the listed options chain.
Learn how analyst ratings is reported and how to read the data →
Frequently asked ASND analyst ratings questions
- What is the ASND consensus price target?
- As of the latest aggregator update, Ascendis Pharma A/S (ASND) carries a consensus 12-month price target of $311.17. Target ranges run from a low of $269.00 to a high of $344.00. The target is the average of the price targets published by sell-side equity analysts covering the name.
- What is the analyst rating consensus on ASND?
- In the October 2026 monthly count, 20 analysts rated ASND, and the distribution tilts to the Buy side: 5 Strong Buy, 15 Buy, 0 Hold, 0 Sell and 0 Strong Sell. Rating consensus moves slowly relative to price; it reflects sell-side conviction over a 12-month horizon rather than near-term momentum.
- What recent ratings actions has ASND seen?
- The five most recent ratings actions on ASND appear on the page above. Sell-side rating changes are watched for two reasons: an upgrade or downgrade with a meaningful target revision moves the consensus and can trigger short-term positioning shifts, and the firm-level rating cluster (multiple firms moving in the same direction within a short window) is a clearer signal than any single action. Options markets often price the implied-vol response within minutes of the announcement.
- How do analyst targets affect ASND options pricing?
- Analyst target revisions tend to be priced in by the lit options market within minutes of publication, but persistent target drift over weeks does correlate with implied-volatility movement. Aggressive target hikes from multiple firms inside a single quarter tighten put skew (downside protection becomes cheaper relative to upside speculation); aggressive cuts widen put skew. The most actionable read is the implied-vol response in the hours after a target change, which is visible on the per-ticker volatility skew page.